X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

Wednesday, April 8, 2020

Graphic of coronavirus infection worldwide

Image by Miroslava Chrienova from Pixabay

Our team is proud to announce that PacBio has been working closely with customers to help in the fight against the COVID-19 pandemic. Scientists in commercial, academic, and government research teams are using highly accurate SMRT Sequencing data to resolve variants of the SARS-CoV-2 virus that exist within one individual or across a population of patients, which is critical to developing and maintaining effective diagnostics, vaccines, and therapeutics.

Many of these efforts are powered by our HiFi reads, which are both long and highly accurate. Such reads are well-suited for applications like viral sequencing, which requires the ability to distinguish variants that may differ by only a handful of single nucleotide variants (SNVs) within a viral gene or across an entire viral genome.

 

Here’s a look at how some research teams are deploying PacBio sequencing for their coronavirus investigations:

 

  • LabCorp, which is actively supporting the response to COVID-19 in the United States and globally, will work closely with PacBio to sequence a large number of SARS-CoV-2 viruses from de-identified positive samples. LabCorp’s scientific teams will use this information to shed light on virus evolution, mutations found in different geographic regions, and implications for disease severity and outcomes, helping to support more informed patient treatment decisions.

“As we strive to rapidly learn as much as possible about the biology of this novel coronavirus to help deal with the current pandemic and also to look ahead to future outbreaks, SMRT Sequencing will give us an accurate, high-resolution view of the pathogen.”

Marcia Eisenberg, PhD, Chief Scientific Officer of LabCorp Diagnostics

  • Scientists at the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases are planning to use the Sequel II System to study virus population diversity and minor variants in samples collected from infected individuals. The information could ultimately be used to support the design of effective vaccines and antibody-based therapies.
  • At the University of California, San Diego, scientists are using SMRT Sequencing data to analyze SARS-CoV-2 samples. They will utilize targeted sequencing data to study the viral genome as well as shotgun metagenomics to characterize the microbiome of nasal tissues responding to a COVID-19 infection.

“We anticipate that the insights we will gain from HiFi sequencing on the Sequel II System will contribute significantly to our knowledge about SARS-CoV-2 and how it operates in people.”

Rob Knight, PhD, Director of the Center for Microbiome Innovation at UC San Diego

  • At the Research Center Borstel, a member of the German Leibniz Association, scientists who focus on lung diseases will be sequencing SARS-CoV-2 samples and other lung pathogens collected from routine diagnostic samples to foster genomic diagnostic applications and study their spread and evolution.
  • Researchers at the Vanderbilt Vaccine Center have used PacBio sequencing technology to study the human B-cell response to the SARS-CoV-2 virus, with the goal of identifying therapeutics or protective antibodies from patient samples.

“We are proud to support the rapidly expanding group of our customers who are engaged in this essential work and believe that the unique nature of SMRT Sequencing will allow them to delve into virus biology and host response research in a way that directly supports the development of much needed diagnostic tests, vaccines and medicines for managing COVID-19,” said Jonas Korlach, PhD, Chief Scientific Officer, PacBio.

 

Visit our COVID-19 Sequencing Resource Center to review the latest protocols, primer sets, and relevant publications.

 

Subscribe for blog updates:

Archives